Edurant

The standard oral dosage for Rilpivirine (Edurant) in treatment-naïve adult patients is 25 mg taken once daily. This dose is consistent whether taken as a standalone tablet or as part of a fixed-dose combination pill (like Odefsey or Complera).

For the long-acting injectable form (Cabenuva), the dosage is more complex. It typically begins with an 'oral lead-in' of Rilpivirine and Cabotegravir tablets for one month to ensure tolerability, followed by an initiation injection (600 mg of cabotegravir and 900 mg of rilpivirine). Maintenance injections are then administered either monthly (400 mg/600 mg) or every two months (600 mg/900 mg), depending on the specific regimen prescribed by the infectious disease specialist.

Rilpivirine is approved for use in pediatric patients aged 12 years and older who weigh at least 35 kg (approximately 77 lbs). The dosage for these adolescents is the same as the adult dose: 25 mg once daily. It is not currently recommended for children under the age of 12 or those weighing less than 35 kg, as the safety and efficacy have not been fully established in these younger populations. Healthcare providers must carefully assess the child's ability to swallow tablets and their adherence to the requirement of taking the medication with a meal.

Renal Impairment

For patients with mild to moderate renal (kidney) impairment, no dosage adjustment of Rilpivirine is typically required. However, in patients with severe renal impairment or end-stage renal disease, Rilpivirine should be used with caution, as drug concentrations may be altered. Because Rilpivirine is highly protein-bound, it is unlikely to be removed by hemodialysis or peritoneal dialysis.

Hepatic Impairment

No dosage adjustment is necessary for patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic (liver) impairment. Rilpivirine has not been extensively studied in patients with severe hepatic impairment (Child-Pugh Class C); therefore, its use is not recommended in this population.

Elderly Patients

Clinical studies of Rilpivirine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

To ensure Rilpivirine works correctly, patients must follow these specific instructions:

• Take with a Meal: This is the most critical instruction. Rilpivirine must be taken with a standard, caloric meal. A protein drink, meal replacement shake, or a small piece of fruit is NOT sufficient. The fat and calories in a meal are required to help the body absorb the medication. Taking it on an empty stomach can lead to low blood levels of the drug, which may allow the virus to become resistant.
• Time of Day: It should be taken at the same time every day to maintain a consistent level of medicine in the blood.
• Swallow Whole: Tablets should be swallowed whole with water. Do not crush, chew, or split the tablets, as this can affect how the drug is released into the system.
• Storage: Store Rilpivirine tablets at room temperature (68°F to 77°F or 20°C to 25°C) in the original container to protect them from light and moisture.

If you miss a dose of Rilpivirine, take it as soon as you remember, provided it is within 12 hours of the scheduled time. You must take it with a meal. If more than 12 hours have passed since the scheduled time, skip the missed dose and take the next dose at the regular time. Do not take two doses at once to make up for a missed one. Frequent missed doses can lead to treatment failure and drug resistance.

There is no specific antidote for a Rilpivirine overdose. If an overdose occurs, the patient should be monitored for signs of toxicity, including potential prolongation of the QT interval (a heart rhythm issue). Emergency measures should include standard supportive care, such as monitoring of vital signs and observation of the clinical status. Because Rilpivirine is highly protein-bound, dialysis is unlikely to be beneficial in removing the drug from the system.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this can cause the HIV virus to become harder to treat.

While Rilpivirine is generally better tolerated than older HIV medications, some patients may still experience side effects. Common reactions reported in clinical trials include:

• Insomnia: Difficulty falling asleep or staying asleep is one of the most frequently reported issues. This usually stabilizes after the first few weeks of treatment.
• Headache: Mild to moderate headaches may occur as the body adjusts to the medication.
• Depressive Disorders: This can include feelings of sadness, hopelessness, or low mood. While often mild, it is important to monitor these feelings closely.
• Rash: A mild skin rash may develop. If the rash is severe or accompanied by fever or blisters, it requires immediate medical attention.
• Nausea: Some patients feel slightly sick to their stomach, though taking the medication with a full meal often helps mitigate this.

• Dizziness: A sensation of spinning or lightheadedness, particularly when standing up quickly.
• Abdominal Pain: Discomfort or cramping in the stomach area.
• Vomiting: Persistent nausea leading to emesis.
• Increased Liver Enzymes: Blood tests may show elevated levels of transaminases (ALT/AST), indicating the liver is working harder.
• Decreased Appetite: A noticeable drop in the desire to eat.
• Somnolence: Excessive sleepiness or drowsiness during the day.

• Severe Skin Reactions: Including Stevens-Johnson Syndrome (SJS), which is a medical emergency involving skin peeling and mucous membrane sores.
• Adrenal Insufficiency: In rare cases, Rilpivirine may interfere with the body's ability to produce cortisol, leading to extreme fatigue and low blood pressure.
• Severe Hepatotoxicity: Significant liver damage, characterized by yellowing of the skin or eyes (jaundice).

> Warning: Stop taking Rilpivirine and call your doctor immediately if you experience any of the following serious symptoms:

• Severe Depressive Symptoms: If you experience suicidal thoughts, thoughts of hurting yourself, or extreme changes in mood and behavior. Clinical trials showed that about 5% of patients experienced depressive disorders, and in some cases, these were severe.
• Liver Problems: Symptoms include yellowing of the skin or the whites of your eyes (jaundice), dark 'tea-colored' urine, light-colored stools, nausea, or pain on the right side of your stomach area. This is especially important for patients co-infected with Hepatitis B or C.
• Severe Rash with Systemic Symptoms: A rash accompanied by fever, general malaise, extreme tiredness, muscle or joint aches, blisters, oral lesions, or swelling of the face. This could indicate a hypersensitivity reaction or DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms).
• Heart Rhythm Changes: Feeling like your heart is skipping a beat, fluttering, or beating too fast, which may indicate QT prolongation.

With prolonged use of Rilpivirine, healthcare providers monitor for:

• Changes in Body Fat: Also known as lipodystrophy, this involves the redistribution of body fat (e.g., loss of fat from legs/arms and accumulation in the abdomen or back of the neck). However, this is significantly less common with Rilpivirine than with older classes of HIV drugs.
• Immune Reconstitution Inflammatory Syndrome (IRIS): As the immune system gets stronger, it may begin to fight hidden infections that were already in the body, leading to an inflammatory response. This typically happens early in treatment but is considered a long-term management factor.
• Bone Density Changes: While more commonly associated with NRTIs like Tenofovir, any long-term HIV regimen requires monitoring of bone health.

No FDA black box warnings currently exist for Rilpivirine. Unlike some other HIV medications (like Abacavir or certain Protease Inhibitors), Rilpivirine does not carry the highest level of FDA warning. However, the warnings regarding depressive disorders and hepatotoxicity are considered 'Warnings and Precautions' and are monitored with equal clinical vigilance.

Report any unusual symptoms to your healthcare provider immediately. Early detection of side effects often allows for adjustments that can keep your HIV treatment successful and comfortable.

Rilpivirine is a vital component of HIV therapy, but it must be used with an understanding of its specific risks. The most critical safety point is the requirement for adherence. Because Rilpivirine has a lower 'genetic barrier' to resistance than some other drug classes (like Integrase Inhibitors), missing doses or taking it without enough food can quickly lead to the virus developing mutations that make Rilpivirine—and other drugs in the NNRTI class—ineffective.

As of 2026, there are no FDA black box warnings for Rilpivirine. However, patients should not interpret the absence of a black box warning as an absence of risk. The medication requires careful medical supervision.

• Hepatotoxicity (Liver Toxicity): Cases of liver damage have been reported in patients taking Rilpivirine. The risk is significantly higher in patients who have pre-existing liver conditions, such as Hepatitis B or Hepatitis C co-infection. Doctors will perform liver function tests (LFTs) before starting and during treatment.
• Depressive Disorders: There is a documented risk of depression, anxiety, and suicidal ideation associated with Rilpivirine use. Patients with a history of psychiatric illness should be monitored closely. If you feel a sudden shift in your mental health, contact your provider immediately.
• QT Prolongation: At doses higher than the standard 25 mg, Rilpivirine has been shown to prolong the QT interval of the electrocardiogram (ECG). While the 25 mg dose is generally safe, Rilpivirine should be used with caution when taken with other medications known to cause QT prolongation (like certain antibiotics or antipsychotics).
• Severe Skin Reactions: Though rare, life-threatening skin reactions like Stevens-Johnson Syndrome have occurred. Any rash should be reported to a doctor immediately, especially if it occurs within the first few weeks of starting the drug.

To ensure safety and efficacy, your healthcare provider will require regular lab work:

• Viral Load (HIV-1 RNA): To ensure the virus is being suppressed to undetectable levels.
• CD4+ Cell Count: To monitor the strength of your immune system.
• Liver Function Tests (ALT, AST, Bilirubin): To check for signs of drug-induced liver injury.
• Lipid Profile: To monitor cholesterol and triglyceride levels, which can sometimes fluctuate during HIV therapy.
• Serum Creatinine: To ensure kidney function remains stable, particularly if Rilpivirine is taken in a combination pill containing Tenofovir.

Rilpivirine may cause dizziness or somnolence (sleepiness) in some patients. If you experience these side effects, you should avoid driving or operating heavy machinery until you are certain the medication does not impair your ability to perform these tasks safely.

While there is no direct contraindication between Rilpivirine and alcohol, excessive alcohol consumption can increase the risk of liver toxicity and may interfere with your ability to remember to take your medication with a meal. It is generally advised to limit alcohol intake while on antiretroviral therapy.

Never stop taking Rilpivirine without consulting your doctor. Stopping HIV medication causes the viral load to rebound rapidly, which can lead to a drop in CD4 cells and the development of drug resistance. If the drug must be stopped (e.g., due to a severe side effect), your doctor will likely switch you to an alternative regimen immediately rather than leaving the virus untreated.

> Important: Discuss all your medical conditions, especially liver disease or mental health history, with your healthcare provider before starting Rilpivirine.

Certain drugs must NEVER be used with Rilpivirine because they either drastically reduce Rilpivirine levels (leading to resistance) or cause dangerous toxicities.

• Proton Pump Inhibitors (PPIs): Drugs like Omeprazole, Lansoprazole, and Esomeprazole are strictly contraindicated. They raise gastric pH so much that Rilpivirine cannot be absorbed. This interaction cannot be managed by separating doses.
• Strong CYP3A4 Inducers: Rifampin, Rifapentine, Carbamazepine, Phenytoin, and Phenobarbital speed up the metabolism of Rilpivirine so much that it disappears from the bloodstream, leading to certain treatment failure.
• Systemic Dexamethasone: More than a single dose can reduce Rilpivirine levels significantly.

• H2-Receptor Antagonists: Drugs like Famotidine (Pepcid) or Cimetidine can be used, but with strict timing. They must be taken at least 12 hours before or 4 hours after the Rilpivirine dose.
• Antacids: Aluminum or magnesium hydroxide (Maalox, Mylanta) or calcium carbonate (Tums) must be taken at least 2 hours before or 4 hours after Rilpivirine.
• Macrolide Antibiotics: Erythromycin and Clarithromycin can increase Rilpivirine levels, potentially increasing the risk of side effects like QT prolongation. Azithromycin is the preferred alternative.

• Antifungals: Ketoconazole and Fluconazole can increase Rilpivirine concentrations. While often used together, patients should be monitored for increased side effects.
• Methadone: Rilpivirine does not significantly affect methadone levels, but monitoring for withdrawal or overdose is always standard practice when starting new HIV meds.

• The "Meal" Requirement: As mentioned, Rilpivirine requires a meal for absorption. A high-fat meal is not strictly required, but a standard meal (approx. 500+ calories) is necessary.
• Grapefruit: Grapefruit and grapefruit juice can inhibit CYP3A4, potentially increasing Rilpivirine levels. While not strictly forbidden, it is best to consume grapefruit in moderation.

• St. John's Wort: This herbal supplement is a potent inducer of CYP3A4 and is contraindicated. It will lower Rilpivirine levels and cause the HIV treatment to fail.
• Garlic Supplements: High-dose garlic supplements may theoretically reduce NNRTI levels, though the clinical impact on Rilpivirine is less clear than with protease inhibitors.

• Bilirubin: Rilpivirine can occasionally cause mild increases in indirect bilirubin without indicating liver damage, though this is much less common than with the drug Atazanavir.

For each major interaction, the mechanism is usually related to CYP3A4 induction/inhibition or gastric pH alteration. The clinical consequence is almost always a reduction in efficacy (leading to HIV resistance) or an increase in toxicity (heart rhythm issues).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter acid reducers.

Absolute contraindications are conditions or medications where the risk clearly outweighs any possible benefit. Rilpivirine is absolutely contraindicated in:

1. 1Co-administration with Proton Pump Inhibitors (PPIs): Because Rilpivirine requires an acidic environment to be absorbed, PPIs (like omeprazole) effectively neutralize the drug before it can enter the bloodstream. Using them together is equivalent to not taking the HIV medication at all.
2. 2Co-administration with Potent CYP3A Enzyme Inducers: This includes drugs like Rifampin (used for TB) and certain anticonvulsants (Carbamazepine). These drugs cause the liver to destroy Rilpivirine too quickly.
3. 3St. John's Wort: This herbal remedy is a powerful inducer of the enzymes that break down Rilpivirine.
4. 4Known Hypersensitivity: Patients who have had a previous severe allergic reaction to Rilpivirine or any of the components in the tablet (such as lactose) must not take the medication.

Relative contraindications require a careful risk-benefit analysis by a specialist:

• Severe Hepatic Impairment: Because the drug is metabolized by the liver, those with Child-Pugh Class C impairment may experience dangerously high levels of the drug.
• History of Severe Depression or Psychosis: While not an absolute 'no,' the known risk of Rilpivirine-induced depressive disorders means these patients require much more frequent monitoring.
• Existing QT Prolongation: Patients with a 'long QT' on their baseline ECG or those taking multiple other drugs that affect heart rhythm should be evaluated carefully.

There is some potential for cross-sensitivity between different drugs in the NNRTI class. If a patient has had a severe skin reaction (like SJS) to Efavirenz or Nevirapine, healthcare providers will be extremely cautious about starting Rilpivirine, as the chemical structures share some similarities that the immune system might recognize.

> Important: Your healthcare provider will evaluate your complete medical history, including your 'drug resistance profile,' before prescribing Rilpivirine to ensure it is the safest and most effective option for you.

FDA Pregnancy Category: Rilpivirine is generally considered a safe option during pregnancy. Data from the Antiretroviral Pregnancy Registry (APR) has not shown an increased risk of major birth defects compared to the background rate in the general population.

However, there is a pharmacokinetic concern: during the second and third trimesters, the levels of Rilpivirine in the blood can drop. Because of this, healthcare providers must monitor viral loads more frequently during pregnancy. If the viral load becomes detectable, the regimen may need to be adjusted. Rilpivirine should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.

In the United States and other regions where clean water and infant formula are accessible, the CDC and medical guidelines recommend that mothers living with HIV do not breastfeed their infants. This is to avoid the risk of postnatal transmission of HIV. Additionally, it is known that Rilpivirine is excreted in human milk, and the effects of the drug on a nursing infant are not fully understood.

Rilpivirine is approved for pediatric patients aged 12 to 18 years who weigh at least 35 kg. The safety profile in adolescents is similar to that seen in adults. It is not approved for children under 12 years of age. One specific concern in pediatric populations is adherence; teenagers must be counselled extensively on the importance of taking the pill with a full meal every single day to prevent resistance.

Clinical trials did not include enough patients over 65 to determine if they respond differently. However, older adults are more likely to have decreased kidney or liver function and are often on multiple medications (polypharmacy). The risk of drug-drug interactions, particularly with acid-reducing medications for reflux (GERD), is much higher in the elderly. Providers should also monitor for increased sensitivity to the drug's effects on mood and sleep.

No dose adjustment is required for patients with mild to moderate renal impairment. For those with severe renal impairment (Creatinine Clearance < 30 mL/min), Rilpivirine should be used with caution. It is not removed by dialysis, so 'extra' doses after a dialysis session are not necessary.

No adjustment is needed for mild (Child-Pugh A) or moderate (Child-Pugh B) liver disease. It has not been studied in severe liver disease (Child-Pugh C), and therefore use in these patients is not recommended. Regular monitoring of liver enzymes is standard for all patients with pre-existing liver issues.

> Important: Special populations require individualized medical assessment and more frequent laboratory monitoring to ensure safety.

Rilpivirine is a diarylpyrimidine (DAPY) derivative and a non-nucleoside reverse transcriptase inhibitor (NNRTI). Its molecular mechanism involves binding to a hydrophobic pocket of the HIV-1 reverse transcriptase (RT) enzyme. This binding site is distinct from the substrate-binding site used by NRTIs. By binding to this allosteric site, Rilpivirine inhibits the RNA-dependent and DNA-dependent DNA polymerase activities of RT.

What makes Rilpivirine unique among NNRTIs is its 'flexibility.' The molecule can rotate and adapt its shape within the binding pocket, which allows it to remain effective even when the virus develops common mutations (like K103N) that would make first-generation NNRTIs like Efavirenz useless.

The relationship between Rilpivirine plasma concentration and antiviral response is well-established. Higher concentrations are associated with a greater likelihood of achieving an undetectable viral load. However, there is also a dose-dependent relationship with QT interval prolongation. At a 25 mg dose, the effect on the QT interval is clinically insignificant, but at 75 mg or 150 mg, the prolongation becomes significant. This is why the dose is strictly capped at 25 mg daily.

| Parameter | Value |

|---|---|

| Bioavailability | High (when taken with a meal) |

| Protein Binding | 99.7% (primarily to Albumin) |

| Half-life | ~50 hours (Oral); Weeks (Injectable) |

| Tmax | 4 to 5 hours |

| Metabolism | Hepatic (CYP3A4) |

| Excretion | Fecal (85%), Renal (6%) |

• Molecular Formula: C22H18N4 • HCl (as hydrochloride)
• Molecular Weight: 366.42 g/mol (base); 402.88 g/mol (HCl salt)
• Solubility: Practically insoluble in water over a wide pH range.
• Structure: A diarylpyrimidine derivative characterized by its ability to undergo conformational changes to overcome viral resistance.

Rilpivirine is classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Related medications in this class include Efavirenz (Sustiva), Nevirapine (Viramune), Etravirine (Intelence), and Doravirine (Pifeltro). Among these, Rilpivirine is considered a 'second-generation' NNRTI due to its higher potency and better resistance profile.